2-ブロモプロパンの rasH2 マウスを用いた
吸入による中期がん原性試験報告書

試験番号：0886

TABLES

TABLES

TABLE A CONCENTRATIONS OF 2-BROMOPROPANE IN THE INHALATION CHAMBER OF rasH2 MICE IN THE 26-WEEK CARCINOGENICITY STUDY

TABLE B 1 SURVIVAL ANIMAL NUMBERS: MALE

TABLE B 2 SURVIVAL ANIMAL NUMBERS: FEMALE

TABLE C 1 CLINICAL OBSERVATION: MALE

TABLE C 2 CLINICAL OBSERVATION: FEMALE

TABLE D 1 BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE

TABLE D 2 BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE

TABLE D 3 BODY WEIGHT CHANGES: MALE

TABLE D 4 BODY WEIGHT CHANGES: FEMALE

TABLE E 1 FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS: MALE

TABLE E 2 FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS: FEMALE

TABLE E 3 FOOD CONSUMPTION CHANGES: MALE

TABLE E 4 FOOD CONSUMPTION CHANGES: FEMALE

TABLE F 1 URINALYSIS: MALE

TABLE F 2 URINALYSIS: FEMALE

TABLE G 1 HEMATOLOGY: MALE

TABLE G 2 HEMATOLOGY: FEMALE

TABLES (CONTINUED)

TABLE H 1 BIOCHEMISTRY: MALE

TABLE H 2 BIOCHEMISTRY: FEMALE

TABLE I 1 GROSS FINDINGS: MALE

TABLE I 2 GROSS FINDINGS: FEMALE

TABLE J 1 ORGAN WEIGHT, ABSOLUTE: MALE

TABLE J 2 ORGAN WEIGHT, ABSOLUTE: FEMALE

TABLE K 1 ORGAN WEIGHT, RELATIVE: MALE

TABLE K 2 ORGAN WEIGHT, RELATIVE: FEMALE

TABLE L 1 HISTOPATHOLOGICAL FINDINGS: NEOPLASTIC LESIONS: MALE

TABLE L 2 HISTOPATHOLOGICAL FINDINGS: NEOPLASTIC LESIONS: FEMALE

TABLE M 1 NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS: MALE

TABLE M 2 NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS: FEMALE

TABLE N 1 NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS-TIME RELATED: MALE

TABLE N 2 NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS-TIME RELATED: FEMALE

TABLE O 1 HISTOPATHOLOGICAL FINDINGS: METASTASIS OF TUMOR: MALE

TABLE O 2 HISTOPATHOLOGICAL FINDINGS: METASTASIS OF TUMOR: FEMALE

TABLES (CONTINUED)

TABLE P 1 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS : MALE

TABLE P 2 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS : FEMALE

TABLE Q 1 CAUSE OF DEATH: MALE

TABLE Q 2 CAUSE OF DEATH: FEMALE

TABLE A

CONCENTRATIONS OF 2-BROMOPROPANE IN THE INHALATION CHAMBER OF rasH2 MICE IN THE 26-WEREK CARCINOGENICITY STUDY

CONCENTRATIONS OF 2-BROMOPROPANE IN THE INHALATION CHAMBER
OF rasH2 MICE IN THE 26-WEEK CARCINOGENICITY STUDY

Group Name	Concentration(ppm) Mean ± S.D.
Control	0.0 ± 0.0
67 ppm	66.8 ± 1.2
200 ppm	200.6 ± 3.6
600 ppm	599.2 ± 10.0

TABLE B1

SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1 26
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 1	2	3	4	5	6	7	8	9	10	11	12	13	14
Control	25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
67ppm	25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
200ppm	25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
600ppm	25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1 26
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 15	16	17	18	19	20	21	22	23	24	25	26
Control	25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
67ppm	25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
200ppm	25	24/25	24/25	23/25	23/25	23/25	23/25	23/25	23/25	23/25	22/25	22/25	21/25
		96.0	96.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0	88.0	88.0	84.0
600ppm	25	25/25	25/25	25/25	25/25	25/25	25/25	24/25	24/25	24/25	24/25	24/25	24/25
		100.0	100.0	100.0	100.0	100.0	100.0	96.0	96.0	96.0	96.0	96.0	96.0

Number of survival/ Number of effective animals
Survival rate(%)

TABLE B2

SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1 26
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 1	2	3	4	5	6	7	8	9	10	11	12	13	14
Control	25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
67ppm	25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
200ppm	25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
600ppm	25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1 26
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 15	16	17	18	19	20	21	22	23	24	25	26
Control	25	25/25	25/25	25/25	25/25	24/25	23/25	23/25	23/25	23/25	23/25	23/25	23/25
		100.0	100.0	100.0	100.0	96.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0
67ppm	25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	24/25	24/25	24/25	24/25	24/25
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	96.0	96.0	96.0	96.0	96.0
200ppm	25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	25/25	24/25
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	96.0
600ppm	25	25/25	25/25	25/25	25/25	24/25	23/25	23/25	21/25	21/25	20/25	20/25	19/25
		100.0	100.0	100.0	100.0	96.0	92.0	92.0	84.0	84.0	80.0	80.0	76.0

Number of survival/ Number of effective animals
Survival rate(%)

TABLE C1

CLINICAL OBSERVATION : MALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)
SURVIVAL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	67ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	600ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	67ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	600ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.TAIL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	67ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	600ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	67ppm	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200ppm	21	21	21	21	21	21	21	21	21	21	21	21	21	21
	600ppm	24	24	24	24	24	24	24	24	24	24	24	24	24	24

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)
SURVIVAL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0
	67ppm	0	0	0	0	0	0	0	0	0	0	0	0
	200ppm	0	0	0	0	0	0	0	0	0	0	0	0
	600ppm	0	0	0	1	1	1	1	1	1	1	1	2
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0
	67ppm	0	0	0	0	0	0	0	0	0	0	0	0
	200ppm	0	0	0	0	0	0	0	0	0	0	0	0
	600ppm	0	0	0	0	0	0	0	0	0	0	0	1
M.TAIL	Control	0	0	0	0	0	0	0	0	0	0	0	0
	67ppm	0	0	0	0	0	0	0	0	0	0	0	0
	200ppm	0	0	0	0	0	0	0	0	0	0	0	0
	600ppm	0	0	0	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25
	67ppm	25	25	25	25	25	25	25	25	25	25	25	25
	200ppm	21	21	21	21	21	21	21	21	21	21	21	21
	600ppm	24	24	24	23	23	23	23	23	23	23	23	22

TABLE C2

CLINICAL OBSERVATION : FEMALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)
SURVIVAL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	67ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	600ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	67ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	600ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	67ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	600ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	67ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	600ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	67ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	600ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	23	23	23	23	23	23	23	23	23	23	23	23	23	23
	67ppm	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	200ppm	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	600ppm	19	19	19	19	19	19	19	19	19	19	19	19	19	19

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)
SURVIVAL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0
	67ppm	0	0	0	0	0	0	0	0	0	0	0	0
	200ppm	0	0	0	0	0	0	0	0	0	0	0	0
	600ppm	0	0	0	0	0	0	0	0	0	0	0	1
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0
	67ppm	0	0	0	0	0	0	0	0	1	1	1	1
	200ppm	0	0	0	0	0	0	0	0	0	0	0	0
	600ppm	0	0	0	0	0	0	0	0	0	0	0	1
M.EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0
	67ppm	0	0	0	0	0	0	0	0	0	0	0	0
	200ppm	0	0	0	0	0	0	0	0	0	0	0	0
	600ppm	0	0	0	0	0	0	0	0	0	0	0	1
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0
	67ppm	0	0	0	0	0	0	0	0	1	1	1	1
	200ppm	0	0	0	0	0	0	0	0	0	0	0	0
	600ppm	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0
	67ppm	0	0	0	0	0	0	0	0	0	0	0	0
	200ppm	0	0	0	0	0	0	0	0	0	0	0	0
	600ppm	0	0	0	0	0	0	0	0	0	0	0	1
NON REMARKABLE	Control	23	23	23	23	23	23	23	23	23	23	23	23
	67ppm	24	24	24	24	24	24	24	24	23	23	23	23
	200ppm	24	24	24	24	24	24	24	24	24	24	24	24
	600ppm	19	19	19	19	19	19	19	19	19	19	19	17

TABLE D1

BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : MALE

MEAN BODY WEIGHTS AND SURVIVAL

Week on Study	Control Av.Wt.	Control No. of Surviv. <25>	67ppm Av.Wt.	67ppm % of cont. <25>	67ppm No. of Surviv.	200ppm Av.Wt.	200ppm % of cont. <25>	200ppm No. of Surviv.	600ppm Av.Wt.	600ppm % of cont. <25>	600ppm No. of Surviv.
0	24.4 (25)	25/25	24.4 (25)	100	25/25	24.4 (25)	100	25/25	24.5 (25)	100	25/25
1	25.7 (25)	25/25	24.7 (25)	96	25/25	24.8 (25)	96	25/25	24.6 (25)	96	25/25
2	26.3 (25)	25/25	25.4 (25)	97	25/25	25.5 (25)	97	25/25	25.2 (25)	96	25/25
3	27.1 (25)	25/25	26.0 (25)	96	25/25	25.9 (25)	96	25/25	25.7 (25)	95	25/25
4	27.7 (25)	25/25	26.5 (25)	96	25/25	26.1 (25)	94	25/25	25.9 (25)	94	25/25
5	28.2 (25)	25/25	26.8 (25)	95	25/25	26.5 (25)	94	25/25	26.1 (25)	93	25/25
6	28.9 (25)	25/25	27.4 (25)	95	25/25	27.1 (25)	94	25/25	26.9 (25)	93	25/25
7	29.2 (25)	25/25	28.0 (25)	96	25/25	27.4 (25)	94	25/25	27.4 (25)	94	25/25
8	29.6 (25)	25/25	28.4 (25)	96	25/25	27.8 (25)	94	25/25	27.4 (25)	93	25/25
9	29.6 (25)	25/25	28.5 (25)	96	25/25	28.0 (25)	95	25/25	27.2 (25)	92	25/25
10	30.1 (25)	25/25	28.6 (25)	95	25/25	27.9 (25)	93	25/25	27.0 (25)	90	25/25
11	30.0 (25)	25/25	28.7 (25)	96	25/25	27.9 (25)	93	25/25	27.2 (25)	91	25/25
12	30.1 (25)	25/25	28.8 (25)	96	25/25	27.6 (25)	92	25/25	27.2 (25)	90	25/25
13	30.6 (25)	25/25	29.0 (25)	95	25/25	27.9 (25)	91	25/25	27.5 (25)	90	25/25
14	30.7 (25)	25/25	29.2 (25)	95	25/25	28.0 (25)	91	25/25	27.4 (25)	89	25/25
15	30.4 (25)	25/25	29.1 (25)	96	25/25	27.7 (24)	91	24/25	27.4 (25)	90	25/25
16	30.9 (25)	25/25	29.5 (25)	95	25/25	27.8 (24)	90	24/25	27.3 (25)	88	25/25
17	30.9 (25)	25/25	29.4 (25)	95	25/25	28.3 (23)	92	23/25	27.5 (25)	89	25/25
18	31.3 (25)	25/25	29.8 (25)	95	25/25	28.8 (23)	92	23/25	28.3 (25)	90	25/25
19	31.5 (25)	25/25	30.1 (25)	96	25/25	28.8 (23)	91	23/25	28.6 (25)	91	25/25
20	31.8 (25)	25/25	30.5 (25)	96	25/25	28.8 (23)	91	23/25	28.8 (25)	91	25/25
21	31.7 (25)	25/25	30.5 (25)	96	25/25	28.9 (23)	91	23/25	28.3 (24)	89	24/25
22	32.2 (25)	25/25	30.8 (25)	96	25/25	29.2 (23)	91	23/25	28.6 (24)	89	24/25
23	32.4 (25)	25/25	30.9 (25)	95	25/25	29.6 (23)	91	23/25	28.9 (24)	89	24/25
24	32.3 (25)	25/25	31.0 (25)	96	25/25	29.3 (22)	91	22/25	28.9 (24)	89	24/25
25	32.6 (25)	25/25	31.3 (25)	96	25/25	29.7 (22)	91	22/25	29.2 (24)	90	24/25
26	32.5 (25)	25/25	31.8 (25)	98	25/25	29.7 (22)	91	21/25	29.5 (24)	91	24/25

< >:No.of effective animals, ( ):No.of measured animals Av.Wt. : g

TABLE D2

BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : FEMALE

MEAN BODY WEIGHTS AND SURVIVAL

Week on Study	Control Av.Wt.	Control No. of Surviv. <25>	67ppm Av.Wt.	67ppm % of cont. <25>	67ppm No. of Surviv.	200ppm Av.Wt.	200ppm % of cont. <25>	200ppm No. of Surviv.	600ppm Av.Wt.	600ppm % of cont. <25>	600ppm No. of Surviv.
0	19.7 (25)	25/25	19.7 (25)	100	25/25	19.7 (25)	100	25/25	19.7 (25)	100	25/25
1	20.1 (25)	25/25	20.2 (25)	100	25/25	19.8 (25)	99	25/25	19.7 (25)	98	25/25
2	20.7 (25)	25/25	20.5 (25)	99	25/25	20.5 (25)	99	25/25	20.4 (25)	99	25/25
3	21.2 (25)	25/25	21.1 (25)	100	25/25	20.8 (25)	98	25/25	20.8 (25)	98	25/25
4	21.9 (25)	25/25	21.4 (25)	98	25/25	21.4 (25)	98	25/25	20.9 (25)	95	25/25
5	22.2 (25)	25/25	21.7 (25)	98	25/25	21.2 (25)	95	25/25	21.1 (25)	95	25/25
6	22.4 (25)	25/25	22.6 (25)	101	25/25	22.2 (25)	99	25/25	21.7 (25)	97	25/25
7	22.8 (25)	25/25	22.7 (25)	100	25/25	22.4 (25)	98	25/25	22.0 (25)	96	25/25
8	22.8 (25)	25/25	22.6 (25)	99	25/25	22.3 (25)	98	25/25	22.1 (25)	97	25/25
9	22.9 (25)	25/25	23.0 (25)	100	25/25	22.3 (25)	97	25/25	22.1 (25)	97	25/25
10	22.9 (25)	25/25	23.0 (25)	100	25/25	22.3 (25)	97	25/25	21.8 (25)	95	25/25
11	23.1 (25)	25/25	23.0 (25)	100	25/25	22.7 (25)	98	25/25	22.0 (25)	95	25/25
12	23.1 (25)	25/25	22.8 (25)	99	25/25	22.6 (25)	98	25/25	22.1 (25)	96	25/25
13	23.3 (25)	25/25	23.3 (25)	100	25/25	22.8 (25)	98	25/25	22.1 (25)	95	25/25
14	23.1 (25)	25/25	23.4 (25)	101	25/25	23.0 (25)	100	25/25	22.1 (25)	96	25/25
15	23.3 (25)	25/25	23.5 (25)	101	25/25	22.7 (25)	97	25/25	21.8 (25)	94	25/25
16	23.4 (25)	25/25	23.5 (25)	100	25/25	23.0 (25)	98	25/25	22.8 (25)	97	25/25
17	23.6 (25)	25/25	23.8 (25)	101	25/25	23.6 (25)	100	25/25	22.8 (25)	97	25/25
18	24.2 (25)	25/25	23.9 (25)	99	25/25	24.1 (25)	100	25/25	23.1 (25)	95	25/25
19	24.3 (24)	24/25	24.4 (25)	100	25/25	24.2 (25)	100	25/25	23.1 (24)	95	24/25
20	24.1 (23)	23/25	24.0 (25)	100	25/25	23.5 (25)	98	25/25	23.2 (23)	96	23/25
21	24.3 (23)	23/25	24.0 (25)	99	25/25	23.7 (25)	98	25/25	22.7 (23)	93	23/25
22	24.6 (23)	23/25	24.9 (24)	101	24/25	23.9 (25)	97	25/25	23.6 (22)	96	21/25
23	24.8 (23)	23/25	24.7 (24)	100	24/25	24.3 (25)	98	25/25	23.6 (21)	95	21/25
24	24.5 (23)	23/25	24.9 (24)	102	24/25	24.0 (25)	98	25/25	23.6 (20)	96	20/25
25	24.9 (23)	23/25	25.2 (24)	101	24/25	23.9 (25)	96	25/25	23.2 (20)	93	20/25
26	25.1 (23)	23/25	25.5 (24)	102	24/25	24.2 (25)	96	24/25	23.5 (19)	94	19/25

< >:No. of effective animals, ( ):No. of measured animals Av.Wt. : g

TABLE D3

BODY WEIGHT CHANGES : MALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
SURVIVAL ANIMALS

Group Name	Administration week 0	1	2	3	4	5	6
Control	24.4± 1.2	25.7± 1.1	26.3± 1.3	27.1± 1.2	27.7± 1.3	28.2± 1.4	28.9± 1.4
67ppm	24.4± 1.2	24.7± 1.1*	25.4± 1.2*	26.0± 1.1*	26.5± 1.1*	26.8± 1.1**	27.4± 1.2**
200ppm	24.4± 1.3	24.7± 1.2*	25.4± 1.3	25.8± 1.5**	26.1± 1.5**	26.4± 1.2**	27.0± 1.2**
600ppm	24.5± 1.2	24.6± 1.3**	25.2± 1.4**	25.6± 1.7**	25.9± 1.6**	26.0± 1.8**	26.8± 2.1**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
SURVIVAL ANIMALS

Group Name	Administration week 7	8	9	10	11	12	13
Control	29.2± 1.4	29.6± 1.6	29.6± 1.5	30.1± 1.5	30.0± 1.4	30.1± 1.4	30.6± 1.6
67ppm	28.0± 1.1**	28.4± 1.3*	28.5± 1.5	28.6± 1.4**	28.7± 1.2**	28.8± 1.4*	29.0± 1.3**
200ppm	27.4± 1.3**	27.7± 1.5**	27.8± 1.5**	27.9± 1.3**	27.9± 1.3**	27.7± 1.3**	28.1± 1.4**
600ppm	27.3± 2.1**	27.3± 2.1**	27.1± 2.1**	26.9± 2.1**	27.1± 2.1**	27.1± 2.3**	27.5± 2.1**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
SURVIVAL ANIMALS

Group Name	Administration week 14	15	16	17	18	19	20
Control	30.7± 1.7	30.4± 1.5	30.9± 1.5	30.9± 1.7	31.3± 1.7	31.5± 1.9	31.8± 1.8
67ppm	29.2± 1.3**	29.1± 1.5*	29.5± 1.7*	29.4± 1.8*	29.8± 1.6*	30.1± 2.1	30.5± 2.0
200ppm	28.1± 1.4**	27.8± 1.5**	28.0± 1.5**	28.3± 1.6**	28.7± 1.7**	28.7± 1.8**	28.8± 1.8**
600ppm	27.3± 2.3**	27.4± 2.2**	27.3± 2.2**	27.5± 2.4**	28.4± 2.5**	28.6± 2.4**	28.8± 2.4**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
SURVIVAL ANIMALS

Group Name	Administration week 21	22	23	24	25	26
Control	31.7± 1.8	32.2± 1.8	32.4± 1.6	32.3± 1.6	32.6± 1.8	32.5± 1.8
67ppm	30.5± 2.1	30.8± 2.1*	30.9± 2.0*	31.0± 2.1	31.3± 2.0	31.8± 2.2
200ppm	28.8± 1.8**	29.2± 1.7**	29.5± 1.7**	29.1± 2.0**	29.5± 2.0**	29.8± 2.0**
600ppm	28.3± 2.3**	28.6± 2.1**	28.9± 2.3**	28.9± 2.5**	29.2± 2.4**	29.5± 2.4**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE D4

BODY WEIGHT CHANGES : FEMALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
SURVIVAL ANIMALS

Group Name	Administration week 0	1	2	3	4	5	6
Control	19.8± 0.8	20.1± 0.9	20.7± 1.0	21.3± 1.0	21.9± 0.7	22.4± 1.0	22.5± 0.8
67ppm	19.6± 0.8	20.2± 0.9	20.5± 1.0	21.0± 0.9	21.4± 1.1	21.7± 1.0*	22.5± 0.9
200ppm	19.7± 0.8	19.9± 0.8	20.6± 0.9	20.9± 0.9	21.5± 1.2	21.3± 1.0**	22.2± 1.1
600ppm	19.7± 0.8	19.7± 0.9	20.4± 1.0	20.9± 1.0	20.8± 1.0**	20.8± 0.8**	21.7± 1.3*

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
SURVIVAL ANIMALS

Group Name	Administration week 7	8	9	10	11	12	13
Control	22.9± 1.2	22.9± 1.1	23.1± 1.1	23.0± 1.1	23.2± 1.0	23.2± 1.0	23.4± 1.2
67ppm	22.6± 1.4	22.6± 1.3	22.9± 1.0	22.9± 1.0	23.0± 1.4	22.8± 1.1	23.3± 1.2
200ppm	22.5± 0.9	22.3± 0.9	22.4± 1.0	22.4± 0.8	22.8± 1.2	22.6± 1.4	22.9± 0.8
600ppm	21.7± 1.0**	22.1± 1.4	22.1± 1.0**	21.7± 0.9**	21.9± 0.9**	21.8± 1.0**	22.2± 0.9**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
SURVIVAL ANIMALS

Group Name	Administration week 14	15	16	17	18	19	20
Control	23.3± 0.9	23.2± 0.9	23.5± 1.1	23.6± 1.1	24.3± 1.4	24.4± 1.4	24.1± 1.2
67ppm	23.3± 1.5	23.5± 1.4	23.4± 1.4	23.8± 1.2	23.9± 1.3	24.4± 1.9	24.0± 1.1
200ppm	23.1± 1.3	22.7± 0.9	23.1± 1.0	23.7± 0.9	24.2± 1.3	24.3± 1.3	23.6± 0.9
600ppm	22.1± 1.2**	21.7± 0.7**	22.7± 1.3	22.6± 1.1*	23.3± 1.6	23.1± 1.4*	23.0± 0.9**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
SURVIVAL ANIMALS

Group Name	Administration week 21	22	23	24	25	26
Control	24.3± 1.0	24.6± 1.6	24.8± 1.8	24.5± 1.1	24.9± 1.8	25.1± 1.1
67ppm	24.0± 1.6	24.9± 2.0	24.7± 1.2	24.9± 1.5	25.2± 1.7	25.5± 2.0
200ppm	23.8± 1.1	24.0± 1.4	24.3± 1.3	24.0± 1.1	24.0± 0.9	24.4± 1.2*
600ppm	22.8± 0.7**	23.6± 1.4	23.7± 1.5	23.5± 1.7	23.3± 1.4**	23.5± 1.5**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE E1

FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : MALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

Week on Study	Control Av. FC.	Control No. of Surviv. <25>	67ppm Av. FC.	67ppm % of cont. <25>	67ppm No. of Surviv.	200ppm Av. FC.	200ppm % of cont. <25>	200ppm No. of Surviv.	600ppm Av. FC.	600ppm % of cont. <25>	600ppm No. of Surviv.
1	4.3 (25)	25/25	4.0 (25)	93	25/25	4.1 (25)	95	25/25	4.0 (25)	93	25/25
2	4.4 (25)	25/25	4.2 (25)	95	25/25	4.2 (25)	95	25/25	4.2 (25)	95	25/25
3	4.4 (25)	25/25	4.2 (25)	95	25/25	4.3 (25)	98	25/25	4.2 (25)	95	25/25
4	4.6 (25)	25/25	4.4 (25)	96	25/25	4.3 (25)	93	25/25	4.4 (25)	96	25/25
5	4.5 (25)	25/25	4.4 (25)	98	25/25	4.5 (25)	100	25/25	4.4 (25)	98	25/25
6	4.6 (25)	25/25	4.4 (25)	96	25/25	4.4 (25)	96	25/25	4.4 (25)	96	25/25
7	4.6 (25)	25/25	4.4 (25)	96	25/25	4.4 (25)	96	25/25	4.4 (25)	96	25/25
8	4.6 (25)	25/25	4.4 (25)	96	25/25	4.5 (25)	98	25/25	4.4 (25)	96	25/25
9	4.6 (25)	25/25	4.4 (25)	96	25/25	4.4 (25)	96	25/25	4.3 (25)	93	25/25
10	4.7 (25)	25/25	4.3 (25)	91	25/25	4.3 (25)	91	25/25	4.3 (25)	91	25/25
11	4.5 (25)	25/25	4.3 (25)	96	25/25	4.2 (25)	93	25/25	4.3 (25)	96	25/25
12	4.5 (25)	25/25	4.3 (25)	96	25/25	4.1 (25)	91	25/25	4.3 (25)	96	25/25
13	4.5 (25)	25/25	4.2 (25)	93	25/25	4.1 (25)	91	25/25	4.3 (25)	96	25/25
14	4.5 (25)	25/25	4.2 (25)	93	25/25	4.1 (25)	91	25/25	4.3 (25)	96	25/25
15	4.5 (25)	25/25	4.5 (25)	100	25/25	4.4 (24)	98	24/25	4.7 (25)	104	25/25
16	4.9 (25)	25/25	4.6 (25)	94	25/25	4.5 (24)	92	24/25	4.7 (25)	96	25/25
17	4.8 (25)	25/25	4.4 (25)	92	25/25	4.4 (23)	92	23/25	4.7 (25)	98	25/25
18	4.9 (25)	25/25	4.6 (25)	94	25/25	4.6 (23)	94	23/25	4.8 (25)	98	25/25
19	4.9 (25)	25/25	4.6 (25)	94	25/25	4.5 (23)	92	23/25	4.8 (25)	98	25/25
20	5.0 (25)	25/25	4.8 (25)	96	25/25	4.5 (23)	90	23/25	4.7 (25)	94	25/25
21	5.0 (25)	25/25	4.7 (25)	94	25/25	4.6 (23)	92	23/25	4.8 (24)	96	24/25
22	4.8 (25)	25/25	4.5 (25)	94	25/25	4.4 (23)	92	23/25	4.6 (24)	96	24/25
23	4.7 (25)	25/25	4.5 (25)	96	25/25	4.4 (23)	94	23/25	4.7 (24)	100	24/25
24	4.7 (25)	25/25	4.4 (25)	94	25/25	4.4 (22)	94	22/25	4.6 (24)	98	24/25
25	4.8 (25)	25/25	4.5 (25)	94	25/25	4.4 (22)	92	22/25	4.6 (24)	96	24/25
26	4.8 (25)	25/25	4.6 (25)	96	25/25	4.6 (21)	96	21/25	4.7 (24)	98	24/25

< >:No. of effective animals, ( ):No. of measured animals Av. FC. : g

TABLE E2

FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : FEMALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

Week on Study	Control Av.FC.	Control No.of Surviv. <25>	67ppm Av.FC.	67ppm % of cont. <25>	67ppm No.of Surviv.	200ppm Av.FC.	200ppm % of cont. <25>	200ppm No.of Surviv.	600ppm Av.FC.	600ppm % of cont. <25>	600ppm No.of Surviv.
1	3.6 (25)	25/25	3.5 (25)	97	25/25	3.5 (25)	97	25/25	3.3 (25)	92	25/25
2	3.7 (25)	25/25	3.5 (25)	95	25/25	3.7 (25)	100	25/25	3.7 (25)	100	25/25
3	3.9 (25)	25/25	3.7 (25)	95	25/25	3.9 (25)	100	25/25	3.8 (25)	97	25/25
4	4.0 (25)	25/25	3.8 (25)	95	25/25	4.0 (25)	100	25/25	3.8 (25)	95	25/25
5	4.1 (25)	25/25	4.0 (25)	98	25/25	4.1 (25)	100	25/25	4.0 (25)	98	25/25
6	4.2 (25)	25/25	4.0 (25)	95	25/25	4.1 (25)	98	25/25	3.9 (25)	93	25/25
7	4.2 (25)	25/25	4.0 (25)	95	25/25	4.2 (25)	100	25/25	4.1 (25)	98	25/25
8	4.2 (25)	25/25	4.1 (25)	98	25/25	4.2 (25)	100	25/25	4.1 (25)	98	25/25
9	4.2 (25)	25/25	4.1 (25)	98	25/25	4.1 (25)	98	25/25	4.1 (25)	98	25/25
10	4.1 (25)	25/25	4.0 (25)	98	25/25	4.1 (25)	100	25/25	3.9 (25)	95	25/25
11	4.1 (25)	25/25	4.0 (25)	98	25/25	4.1 (25)	100	25/25	3.9 (25)	95	25/25
12	4.1 (25)	25/25	3.9 (25)	95	25/25	4.0 (25)	98	25/25	3.9 (25)	95	25/25
13	4.0 (25)	25/25	4.0 (25)	100	25/25	4.1 (25)	103	25/25	3.9 (25)	98	25/25
14	4.1 (25)	25/25	4.0 (25)	98	25/25	4.2 (25)	102	25/25	4.1 (25)	100	25/25
15	4.3 (25)	25/25	4.4 (25)	102	25/25	4.6 (25)	107	25/25	4.5 (25)	105	25/25
16	4.6 (25)	25/25	4.5 (25)	98	25/25	4.7 (25)	102	25/25	4.7 (25)	102	25/25
17	4.6 (25)	25/25	4.5 (25)	98	25/25	4.7 (25)	102	25/25	4.5 (25)	98	25/25
18	4.7 (25)	25/25	4.5 (25)	96	25/25	4.7 (25)	100	25/25	4.6 (25)	98	25/25
19	4.6 (24)	24/25	4.7 (25)	102	25/25	4.7 (25)	102	25/25	4.6 (24)	100	24/25
20	4.7 (23)	23/25	4.4 (25)	94	25/25	4.4 (25)	94	25/25	4.5 (23)	96	23/25
21	4.8 (23)	23/25	4.6 (25)	96	25/25	4.7 (25)	98	25/25	4.6 (23)	96	23/25
22	4.5 (23)	23/25	4.5 (24)	100	24/25	4.4 (25)	98	25/25	4.4 (21)	98	21/25
23	4.6 (23)	23/25	4.4 (24)	96	24/25	4.4 (25)	96	25/25	4.6 (21)	100	21/25
24	4.4 (23)	23/25	4.4 (24)	100	24/25	4.3 (25)	98	25/25	4.3 (20)	98	20/25
25	4.5 (23)	23/25	4.5 (24)	100	24/25	4.3 (25)	96	25/25	4.3 (20)	96	20/25
26	4.4 (23)	23/25	4.4 (24)	100	24/25	4.4 (24)	100	24/25	4.3 (19)	98	19/25

< >:No.of effective animals, ( ):No.of measured animals Av.FC. : g

TABLE E3

FOOD CONSUMPTION CHANGES : MALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
SURVIVAL ANIMALS

Group Name	Administration week 1	2	3	4	5	6	7
Control	4.3± 0.2	4.4± 0.2	4.4± 0.3	4.6± 0.3	4.5± 0.3	4.6± 0.3	4.6± 0.4
67ppm	4.0± 0.2**	4.2± 0.3	4.2± 0.4	4.4± 0.4	4.4± 0.4	4.4± 0.4	4.4± 0.4
200ppm	4.1± 0.3	4.2± 0.3	4.3± 0.4	4.4± 0.4	4.5± 0.3	4.4± 0.3	4.4± 0.3
600ppm	4.0± 0.3**	4.2± 0.3	4.2± 0.3	4.4± 0.3	4.4± 0.3	4.4± 0.5	4.4± 0.3

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
SURVIVAL ANIMALS

Group Name	Administration week 8	9	10	11	12	13	14
Control	4.6± 0.5	4.6± 0.5	4.7± 0.5	4.5± 0.3	4.5± 0.4	4.5± 0.5	4.5± 0.5
67ppm	4.4± 0.4	4.4± 0.4	4.3± 0.4**	4.3± 0.3	4.3± 0.3*	4.2± 0.3*	4.2± 0.3**
200ppm	4.5± 0.3	4.5± 0.3	4.4± 0.3*	4.3± 0.3	4.2± 0.3**	4.2± 0.3	4.2± 0.3**
600ppm	4.4± 0.4	4.3± 0.3	4.3± 0.4**	4.3± 0.3	4.3± 0.4*	4.3± 0.3	4.3± 0.4

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
SURVIVAL ANIMALS

Group Name	Administration week 15	16	17	18	19	20	21
Control	4.5± 0.4	4.9± 0.5	4.8± 0.6	4.9± 0.5	4.9± 0.6	5.0± 0.5	5.0± 0.6
67ppm	4.5± 0.3	4.6± 0.4*	4.4± 0.4*	4.6± 0.3**	4.6± 0.5	4.8± 0.4	4.7± 0.4*
200ppm	4.5± 0.4	4.5± 0.4**	4.4± 0.4*	4.6± 0.4*	4.5± 0.4	4.5± 0.3**	4.7± 0.4
600ppm	4.7± 0.4	4.7± 0.5	4.7± 0.5	4.8± 0.5	4.8± 0.5	4.7± 0.4*	4.8± 0.4

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
SURVIVAL ANIMALS

Group Name	Administration week 22	23	24	25	26
Control	4.8± 0.5	4.7± 0.4	4.7± 0.4	4.8± 0.5	4.8± 0.4
67ppm	4.5± 0.3*	4.5± 0.3	4.4± 0.4*	4.5± 0.4	4.6± 0.3
200ppm	4.4± 0.4**	4.4± 0.3	4.4± 0.3**	4.4± 0.3	4.6± 0.3
600ppm	4.6± 0.4	4.7± 0.5	4.6± 0.4	4.6± 0.5	4.7± 0.4

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE E4

FOOD CONSUMPTION CHANGES : FEMALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
SURVIVAL ANIMALS

Group Name	Administration week 1	2	3	4	5	6	7
Control	3.6± 0.3	3.7± 0.3	3.9± 0.3	4.0± 0.3	4.1± 0.3	4.2± 0.3	4.2± 0.3
67ppm	3.5± 0.3	3.5± 0.3*	3.7± 0.3*	3.8± 0.3*	4.0± 0.3	4.0± 0.3*	4.1± 0.4
200ppm	3.5± 0.3	3.7± 0.3	3.9± 0.3	4.0± 0.3	4.1± 0.3	4.2± 0.3	4.3± 0.3
600ppm	3.3± 0.2*	3.7± 0.3	3.8± 0.2	3.8± 0.3*	4.0± 0.4	3.9± 0.3**	4.0± 0.3*

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
SURVIVAL ANIMALS

Group Name	Administration week 8	9	10	11	12	13	14
Control	4.2± 0.3	4.2± 0.3	4.2± 0.3	4.1± 0.3	4.1± 0.2	4.0± 0.3	4.1± 0.3
67ppm	4.1± 0.4	4.1± 0.4	4.0± 0.3	4.0± 0.3	3.9± 0.3*	4.0± 0.4	4.0± 0.3
200ppm	4.2± 0.3	4.2± 0.4	4.1± 0.3	4.1± 0.3	4.0± 0.3	4.1± 0.3	4.2± 0.4
600ppm	4.1± 0.4	4.0± 0.3	3.9± 0.3**	3.9± 0.3*	3.8± 0.3*	3.9± 0.3	4.1± 0.3

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
SURVIVAL ANIMALS

Group Name	Administration week 15	16	17	18	19	20	21
Control	4.3± 0.3	4.6± 0.2	4.6± 0.3	4.8± 0.4	4.7± 0.3	4.7± 0.4	4.8± 0.4
67ppm	4.4± 0.5	4.5± 0.5	4.5± 0.4	4.5± 0.4	4.7± 0.7	4.4± 0.3*	4.6± 0.4
200ppm	4.6± 0.6	4.8± 0.4	4.7± 0.4	4.7± 0.4	4.7± 0.5	4.5± 0.4	4.7± 0.4
600ppm	4.4± 0.4	4.6± 0.5	4.5± 0.4	4.6± 0.5	4.6± 0.4	4.5± 0.4	4.7± 0.4

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
UNIT : g
REPORT TYPE : A1 26
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
SURVIVAL ANIMALS

Group Name	Administration week 22	23	24	25	26
Control	4.5± 0.3	4.6± 0.4	4.4± 0.3	4.5± 0.4	4.4± 0.4
67ppm	4.5± 0.4	4.4± 0.5	4.4± 0.5	4.5± 0.4	4.4± 0.4
200ppm	4.4± 0.4	4.4± 0.4	4.3± 0.4	4.3± 0.4	4.4± 0.3
600ppm	4.4± 0.4	4.4± 0.5	4.3± 0.5	4.3± 0.4	4.3± 0.5

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE F1

URINALYSIS : MALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

URINALYSIS

Group Name	NO. of Animals	pH 5.0	6.0	6.5	7.0	7.5	8.0	8.5	CHI	Protein −	±	+	2+	3+	4+	CHI	Glucose −	±	+	2+	3+	4+	CHI	Ketone body −	±	+	2+	3+	4+	CHI	Occult blood −	±	+	2+	3+	CHI
Control	18	0	0	0	2	2	0	14		0	4	13	1	0	0		18	0	0	0	0	0		0	7	9	2	0	0		18	0	0	0	0	
67ppm	11	0	0	2	0	0	1	8		0	6	5	0	0	0		11	0	0	0	0	0		3	4	2	2	0	0		11	0	0	0	0	
200ppm	10	0	0	1	2	1	3	3	*	0	3	5	2	0	0		10	0	0	0	0	0		1	5	3	1	0	0		10	0	0	0	0	
600ppm	6	0	1	0	1	1	0	3		1	4	0	1	0	0	*	6	0	0	0	0	0		1	3	1	1	0	0		6	0	0	0	0	

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

URINALYSIS

Group Name	NO. of Animals	Urobilinogen ±	+	2+	3+	4+	CHI
Control	18	18	0	0	0	0	
67ppm	11	11	0	0	0	0	
200ppm	10	10	0	0	0	0	
600ppm	6	6	0	0	0	0	

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

TABLE F2

URINALYSIS : FEMALE

STUDY NO. : 0886 URINALYSIS
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

Group Name	NO. of Animals	pH 5.0	6.0	6.5	7.0	7.5	8.0	8.5	CHI	Protein −	±	+	2+	3+	4+	CHI	Glucose −	±	+	2+	3+	4+	CHI	Ketone body −	±	+	2+	3+	4+	CHI	Occult blood −	±	+	2+	3+	CHI
Control	23	0	1	6	7	6	3	0		2	12	9	0	0	0		23	0	0	0	0	0		1	11	9	2	0	0		23	0	0	0	0	
67ppm	22	0	0	3	4	9	4	2		2	10	10	0	0	0		22	0	0	0	0	0		1	12	8	1	0	0		22	0	0	0	0	
200ppm	24	0	0	3	4	5	9	3		2	10	12	0	0	0		24	0	0	0	0	0		2	12	8	2	0	0		24	0	0	0	0	
600ppm	13	0	0	2	2	2	7	0		2	5	5	1	0	0		13	0	0	0	0	0		0	8	4	1	0	0		13	0	0	0	0	

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

URINALYSIS

Group Name	NO. of Animals	Urobilinogen ±	+	2+	3+	4+	CHI
Control	23	23	0	0	0	0	
67ppm	22	22	0	0	0	0	
200ppm	24	24	0	0	0	0	
600ppm	13	13	0	0	0	0	

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

TABLE G1

HEMATOLOGY : MALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	RED BLOOD CELL $10^6/\mu\ell$		HEMOGLOBIN g/dℓ		HEMATOCRIT %		MCV fℓ		MCH pg		MCHC g/dℓ		PLATELET $10^3/\mu\ell$	
Control	25	10.78±	0.33	17.1±	0.4	51.4±	1.6	47.7±	0.8	15.8±	0.3	33.2±	0.6	1269±	91
67ppm	25	10.57±	0.92	16.7±	1.3	50.7±	3.6	48.0±	1.5	15.8±	0.3	33.0±	0.6	1268±	97
200ppm	21	10.74±	0.34	17.1±	0.4	51.8±	1.4	48.3±	0.9*	16.0±	0.3	33.1±	0.6	1224±	47*
600ppm	24	9.98±	0.39**	16.6±	0.5**	49.8±	1.7**	49.9±	1.4**	16.6±	0.4**	33.3±	0.5	1069±	97**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

(HCL070)

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	RETICULOCYTE %
Control	25	2.3± 0.2
67ppm	25	3.0± 2.6
200ppm	21	2.2± 0.2
600ppm	24	2.2± 0.5

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	WBC $10^3/\mu\ell$		Differential WBC (%) NEUTRO		LYMPHO		MONO		EOSINO		BASO		OTHER	
Control	25	1.38±	0.49	25±	8	69±	8	4±	4	2±	1	0±	0	0±	0
67ppm	25	1.33±	0.39	22±	7	70±	9	5±	5	3±	2	0±	0	0±	0
200ppm	21	1.24±	0.48	20±	8	74±	9	3±	3	3±	1	0±	0	0±	1
600ppm	24	2.13±	4.82	23±	11	68±	17	7±	10	3±	2	0±	0	0±	0

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE G2

HEMATOLOGY : FEMALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	RED BLOOD CELL $10^6/\mu\ell$	HEMOGLOBIN g/dℓ	HEMATOCRIT %	MCV f ℓ	MCH p g	MCHC g/dℓ	PLATELET $10^3/\mu\ell$
Control	23	10.58± 0.53	17.0± 0.8	51.1± 2.1	48.3± 0.9	16.1± 0.3	33.3± 0.6	1178± 140
67ppm	24	10.54± 0.37	16.9± 0.7	50.8± 1.5	48.2± 0.7	16.1± 0.4	33.3± 0.9	1179± 66
200ppm	24	10.44± 0.28	17.0± 0.4	50.8± 1.4	48.7± 0.7	16.2± 0.2	33.4± 0.4	1104± 111**
600ppm	18	10.18± 0.34**	17.0± 0.6	50.9± 1.6	50.1± 0.8**	16.7± 0.2**	33.4± 0.5	957± 56**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	RETICULOCYTE %
Control	23	2.9± 1.4
67ppm	24	2.5± 0.9
200ppm	24	2.6± 0.5
600ppm	18	2.5± 0.5

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	WBC $10^3/\mu\ell$		Differential WBC (%) NEUTRO		LYMPHO		MONO		EOSINO		BASO		OTHER	
Control	23	1.80±	1.04	25±	18	71±	18	2±	1	3±	2	0±	0	0±	0
67ppm	24	1.69±	0.63	22±	10	70±	12	5±	7	3±	2	0±	0	0±	0
200ppm	24	1.51±	0.75	25±	9	71±	9	2±	1	2±	1	0±	0	0±	0
600ppm	18	1.32±	0.55	32±	14*	59±	13**	6±	8*	2±	1	0±	0	0±	0

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE H1

BIOCHEMISTRY : MALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	TOTAL PROTEIN g/dℓ	ALBUMIN g/dℓ	A/G RATIO	T-BILIRUBIN mg/dℓ	GLUCOSE mg/dℓ	T-CHOLESTEROL mg/dℓ	TRIGLYCERIDE mg/dℓ
Control	25	5.2± 0.2	2.9± 0.1	1.3± 0.1	0.06± 0.01	208± 23	77± 12	45± 16
67ppm	25	5.2± 0.2	2.9± 0.1	1.3± 0.1	0.05± 0.01	206± 27	79± 8	49± 15
200ppm	21	5.1± 0.1	2.9± 0.1	1.3± 0.1	0.06± 0.01	206± 26	73± 9	40± 14
600ppm	24	5.2± 0.2	2.9± 0.1	1.3± 0.1	0.06± 0.01	209± 31	71± 7	37± 11

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	PHOSPHOLIPID mg/dl	AST U/L	ALT U/L	LDH U/L	ALP U/L	G-GTP U/L	CK U/L
Control	25	161± 22	54± 11	20± 6	233± 57	203± 20	0.2± 0.4	71± 34
67ppm	25	164± 15	60± 16	23± 8	226± 50	217± 23	0.2± 0.3	60± 13
200ppm	21	152± 21	55± 16	19± 5	229± 44	216± 13	0.3± 0.4	78± 44
600ppm	24	148± 15	65± 28	24± 12	258± 52	219± 28*	0.3± 0.3	66± 24

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	UREA NITROGEN mg/dl	SODIUM mEq/ℓ	POTASSIUM mEq/ℓ	CHLORIDE mEq/ℓ	CALCIUM mg/dl	INORGANIC PHOSPHORUS mg/dl
Control	25	26.3± 7.2	152± 3	3.7± 0.3	115± 4	8.5± 0.3	5.4± 0.7
67ppm	25	23.0± 3.6	151± 2	3.6± 0.2	115± 3	8.5± 0.2	5.5± 0.6
200ppm	21	23.4± 5.3	151± 1	3.6± 0.2	117± 2	8.6± 0.2	5.3± 0.7
600ppm	24	22.9± 5.8	151± 2	3.8± 0.3	117± 5	8.6± 0.3	5.7± 0.7

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE H2

BIOCHEMISTRY : FEMALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	TOTAL PROTEIN g/dℓ	ALBUMIN g/dℓ	A/G RATIO	T-BILIRUBIN mg/dℓ	GLUCOSE mg/dℓ	T-CHOLESTEROL mg/dℓ	TRIGLYCERIDE mg/dℓ
Control	23	5.2± 0.1	3.0± 0.1	1.4± 0.1	0.05± 0.01	175± 36	62± 11	35± 13
67ppm	24	5.3± 0.2	3.1± 0.1	1.4± 0.1	0.05± 0.01	191± 24	64± 8	36± 10
200ppm	23	5.3± 0.2	3.1± 0.1	1.4± 0.1	0.05± 0.01	202± 26*	64± 7	32± 11
600ppm	19	5.3± 0.2*	3.1± 0.2	1.4± 0.1	0.06± 0.02**	197± 44*	69± 13	37± 16

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	PHOSPHOLIPID mg/dℓ		AST U/L		ALT U/L		LDH U/L		ALP U/L		G-GTP U/L		CK U/L	
Control	23	127±	20	76±	18	22±	5	209±	42	324±	39	0.3±	0.3	86±	48
67ppm	24	132±	17	76±	25	22±	4	215±	37	322±	46	0.3±	0.3	81±	34
200ppm	23	130±	13	78±	25	21±	5	213±	40	311±	35	0.3±	0.4	86±	44
600ppm	19	135±	21	97±	52	28±	18	407±	605	309±	36	0.3±	0.4	157±	317

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	UREA NITROGEN mg/dℓ	SODIUM mEq/ℓ	POTASSIUM mEq/ℓ	CHLORIDE mEq/ℓ	CALCIUM mg/dℓ	INORGANIC PHOSPHORUS mg/dℓ
Control	23	18.1± 3.1	152± 2	3.3± 0.2	117± 2	8.9± 0.2	5.7± 0.9
67ppm	24	16.3± 3.3	152± 2	3.3± 0.2	117± 2	8.9± 0.2	5.4± 0.8
200ppm	23	18.7± 2.9	151± 2	3.3± 0.2	116± 2	8.9± 0.2	5.6± 0.9
600ppm	19	19.2± 6.6	152± 2	3.4± 0.4	118± 4	8.9± 0.3	5.4± 0.9

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE I1

GROSS FINDINGS : MALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1
SEX : MALE

GROSS FINDINGS (SUMMARY)
ALL ANIMALS (0- 27W)

Organ	Findings	Group Name / NO. of Animals	Control 25 (%)	67ppm 25 (%)	200ppm 25 (%)	600ppm 25 (%)
subcutis	edema		0 (0)	0 (0)	0 (0)	1 (4)
	mass		0 (0)	0 (0)	1 (4)	1 (4)
lung	red zone		0 (0)	0 (0)	1 (4)	0 (0)
	nodule		1 (4)	2 (8)	1 (4)	0 (0)
lymph node	enlarged		0 (0)	0 (0)	1 (4)	0 (0)
thymus	enlarged		0 (0)	1 (4)	1 (4)	1 (4)
	atrophic		0 (0)	0 (0)	1 (4)	0 (0)
spleen	enlarged		0 (0)	0 (0)	2 (8)	0 (0)
	black zone		3 (12)	1 (4)	6 (24)	1 (4)
	nodule		1 (4)	1 (4)	1 (4)	1 (4)
stomach	forestomach:nodule		0 (0)	0 (0)	0 (0)	1 (4)
liver	enlarged		0 (0)	0 (0)	1 (4)	0 (0)
	white zone		0 (0)	0 (0)	1 (4)	0 (0)
	red zone		1 (4)	1 (4)	0 (0)	0 (0)
	nodule		0 (0)	1 (4)	0 (0)	1 (4)
kidney	white zone		0 (0)	0 (0)	1 (4)	0 (0)
testis	small		0 (0)	0 (0)	1 (4)	24 (96)
prep/cli gl	enlarged		0 (0)	0 (0)	1 (4)	0 (0)
peritoneum	nodule		0 (0)	0 (0)	0 (0)	1 (4)
abdominal c	hemorrhage		0 (0)	0 (0)	1 (4)	0 (0)
other	tail:nodule		0 (0)	0 (0)	0 (0)	1 (4)
	lower jaw:nodule		0 (0)	0 (0)	1 (4)	0 (0)

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1
SEX : MALE

GROSS FINDINGS (SUMMARY)
ALL ANIMALS (0- 27W)

Organ	Findings	Group Name / NO. of Animals	Control 25	(%)	67ppm 25	(%)	200ppm 25	(%)	600ppm 25	(%)
other	nose:nodule		0	(0)	0	(0)	0	(0)	1	(4)

TABLE I2

GROSS FINDINGS : FEMALE

Organ	Findings	Group Name / NO. of Animals	Control 25	(%)	67ppm 25	(%)	200ppm 25	(%)	600ppm 25	(%)
subcutis	mass		0	(0)	1	(4)	0	(0)	0	(0)
lung	red		0	(0)	0	(0)	0	(0)	1	(4)
	white zone		1	(4)	0	(0)	0	(0)	1	(4)
	nodule		2	(8)	1	(4)	5	(20)	4	(16)
lymph node	enlarged		1	(4)	0	(0)	0	(0)	1	(4)
thymus	enlarged		0	(0)	0	(0)	0	(0)	2	(8)
	atrophic		0	(0)	0	(0)	0	(0)	1	(4)
spleen	enlarged		1	(4)	0	(0)	1	(4)	2	(8)
	black zone		2	(8)	2	(8)	1	(4)	4	(16)
	nodule		1	(4)	2	(8)	0	(0)	0	(0)
stomach	forestomach:nodule		0	(0)	1	(4)	1	(4)	1	(4)
	forestomach:thick		0	(0)	0	(0)	0	(0)	1	(4)
	glandular stomach:nodule		0	(0)	0	(0)	0	(0)	1	(4)
small intes	nodule		1	(4)	0	(0)	0	(0)	0	(0)
liver	enlarged		0	(0)	0	(0)	0	(0)	1	(4)
	red zone		0	(0)	1	(4)	0	(0)	0	(0)
	nodule		0	(0)	0	(0)	1	(4)	0	(0)
kidney	enlarged		0	(0)	0	(0)	0	(0)	1	(4)
vagina	nodule		0	(0)	0	(0)	1	(4)	0	(0)
mediastinum	mass		1	(4)	0	(0)	0	(0)	1	(4)
abdominal c	hemorrhage		0	(0)	1	(4)	0	(0)	0	(0)
thoracic ca	hemorrhage		2	(8)	0	(0)	0	(0)	0	(0)

Organ	Findings	Group Name / NO. of Animals	Control 25	(%)	67ppm 25	(%)	200ppm 25	(%)	600ppm 25	(%)
thoracic ca	pleural fluid		0	(0)	0	(0)	0	(0)	4	(16)
other	ear:nodule		0	(0)	0	(0)	0	(0)	1	(4)
	nose:nodule		0	(0)	0	(0)	1	(4)	0	(0)
whole body	anemic		0	(0)	0	(0)	1	(4)	0	(0)

TABLE J1

ORGAN WEIGHT, ABSOLUTE : MALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1
SEX : MALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	Body Weight	THYMUS	ADRENALS	TESTES	HEART	LUNGS
Control	25	28.5± 2.0	0.047± 0.013	0.014± 0.003	0.269± 0.019	0.188± 0.019	0.166± 0.011
67ppm	25	28.0± 2.2	0.061± 0.073	0.014± 0.003	0.254± 0.020**	0.181± 0.014	0.163± 0.013
200ppm	21	26.8± 1.9*	0.044± 0.010	0.014± 0.003	0.206± 0.040**	0.175± 0.010	0.165± 0.012
600ppm	24	26.1± 2.5**	0.044± 0.056**	0.014± 0.004	0.066± 0.006**	0.179± 0.021	0.163± 0.011

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1
SEX : MALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	KIDNEYS	SPLEEN	LIVER	BRAIN
Control	25	0.594± 0.060	0.080± 0.071	1.296± 0.101	0.487± 0.014
67ppm	25	0.559± 0.032	0.072± 0.019	1.253± 0.070	0.486± 0.015
200ppm	21	0.553± 0.032	0.066± 0.012	1.212± 0.087**	0.484± 0.016
600ppm	24	0.558± 0.050	0.081± 0.039	1.229± 0.101*	0.477± 0.015

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE J2

ORGAN WEIGHT, ABSOLUTE : FEMALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1
SEX : FEMALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	Body Weight	THYMUS	ADRENALS	OVARIES	HEART	LUNGS
Control	23	21.6± 1.0	0.050± 0.016	0.016± 0.002	0.034± 0.005	0.147± 0.010	0.188± 0.137
67ppm	24	21.9± 1.7	0.046± 0.011	0.016± 0.003	0.030± 0.004*	0.148± 0.012	0.161± 0.009
200ppm	24	21.1± 0.7*	0.040± 0.014*	0.016± 0.003	0.029± 0.004**	0.147± 0.012	0.162± 0.022
600ppm	19	20.5± 1.2**	0.056± 0.111**	0.015± 0.002	0.026± 0.005**	0.142± 0.012	0.195± 0.138

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1
SEX : FEMALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	KIDNEYS	SPLEEN	LIVER	BRAIN
Control	23	0.414± 0.026	0.085± 0.017	1.053± 0.069	0.504± 0.013
67ppm	24	0.419± 0.024	0.084± 0.016	1.051± 0.082	0.506± 0.015
200ppm	24	0.409± 0.018	0.079± 0.008	1.046± 0.063	0.504± 0.014
600ppm	19	0.404± 0.029	0.073± 0.008*	1.037± 0.104	0.490± 0.018*

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE K1

ORGAN WEIGHT, RELATIVE : MALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1
SEX : MALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	Body Weight (g)	THYMUS	ADRENALS	TESTES	HEART	LUNGS
Control	25	28.5± 2.0	0.163± 0.045	0.050± 0.011	0.946± 0.080	0.661± 0.056	0.583± 0.043
67ppm	25	28.0± 2.2	0.219± 0.263	0.050± 0.012	0.912± 0.102	0.650± 0.055	0.586± 0.053
200ppm	21	26.8± 1.9*	0.166± 0.033	0.054± 0.011	0.770± 0.153**	0.655± 0.042	0.619± 0.062
600ppm	24	26.1± 2.5**	0.163± 0.178**	0.054± 0.013	0.253± 0.021**	0.688± 0.078	0.629± 0.049**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1
SEX : MALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	KIDNEYS	SPLEEN	LIVER	BRAIN
Control	25	2.082± 0.160	0.279± 0.241	4.546± 0.199	1.714± 0.099
67ppm	25	2.003± 0.124	0.258± 0.065	4.487± 0.208	1.748± 0.148
200ppm	21	2.073± 0.157	0.245± 0.038	4.531± 0.190	1.814± 0.121*
600ppm	24	2.142± 0.107	0.314± 0.153**	4.720± 0.233*	1.841± 0.149**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE K2

ORGAN WEIGHT, RELATIVE : FEMALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1
SEX : FEMALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	Body Weight (g)	THYMUS	ADRENALS	OVARIES	HEART	LUNGS
Control	23	21.6± 1.0	0.231± 0.069	0.074± 0.010	0.155± 0.019	0.680± 0.043	0.884± 0.730
67ppm	24	21.9± 1.7	0.210± 0.049	0.074± 0.013	0.139± 0.021*	0.676± 0.054	0.740± 0.053
200ppm	24	21.1± 0.7*	0.191± 0.064	0.075± 0.014	0.140± 0.016*	0.698± 0.059	0.770± 0.102
600ppm	19	20.5± 1.2**	0.271± 0.525**	0.074± 0.010	0.128± 0.021**	0.694± 0.046	0.984± 0.854

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1
SEX : FEMALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (27W)

Group Name	NO. of Animals	KIDNEYS	SPLEEN	LIVER	BRAIN
Control	23	1.912± 0.108	0.392± 0.079	4.869± 0.284	2.335± 0.128
67ppm	24	1.920± 0.113	0.385± 0.067	4.809± 0.248	2.323± 0.128
200ppm	24	1.944± 0.091	0.377± 0.037	4.969± 0.238	2.394± 0.106
600ppm	19	1.973± 0.125	0.356± 0.039	5.046± 0.249	2.398± 0.128

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE L1

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : MALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0- 27W)

Organ	Findings	Group Name / No. of animals on Study	Control 25	67ppm 25	200ppm 25	600ppm 25
{Integumentary system/appandage}						
skin/app	squamous cell papilloma		<25> 0 (0%)	<25> 0 (0%)	<25> 0 (0%)	<25> 1 (4%)
subcutis	hemangioma		<25> 0 (0%)	<25> 0 (0%)	<25> 0 (0%)	<25> 1 (4%)
	hemangiosarcoma		0 (0%)	0 (0%)	1 (4%)	1 (4%)
{Respiratory system}						
lung	bronchiolar-alveolar adenoma		<25> 3 (12%)	<25> 3 (12%)	<25> 2 (8%)	<25> 5 (20%)
	bronchiolar-alveolar carcinoma		0 (0%)	1 (4%)	3 (12%)	4 (16%)
{Hematopoietic system}						
lymph node	malignant lymphoma		<25> 0 (0%)	<25> 0 (0%)	<25> 2 (8%)	<25> 0 (0%)
thymus	malignant lymphoma		<24> 0 (0%)	<25> 1 (4%)	<25> 0 (0%)	<25> 1 (4%)
spleen	hemangiosarcoma		<25> 1 (4%)	<25> 1 (4%)	<25> 2 (8%)	<25> 2 (8%)
{Circulatory system}						
lymph vess	lymphangioma		<25> 0 (0%)	<25> 0 (0%)	<25> 0 (0%)	<25> 1 (4%)
{Digestive system}						
oral cavity	squamous cell carcinoma		<25> 0 (0%)	<25> 0 (0%)	<25> 1 (4%)	<25> 0 (0%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 25	67ppm 25	200ppm 25	600ppm 25
{Digestive system}						
stomach			<25>	<25>	<25>	<25>
	squamous cell carcinoma		0 (0%)	0 (0%)	0 (0%)	1 (4%)
liver			<25>	<25>	<25>	<25>
	hepatocellular adenoma		0 (0%)	1 (4%)	1 (4%)	0 (0%)
{Special sense organs/appendage}						
Harder gl			<25>	<25>	<25>	<25>
	adenoma		0 (0%)	0 (0%)	1 (4%)	0 (0%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

TABLE L2

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : FEMALE

Organ	Findings	Group Name / No. of animals on Study	Control 25	67ppm 25	200ppm 25	600ppm 25
{Integumentary system/appandage}						
subcutis	hemangioma		<25> 0 (0%)	<25> 1 (4%)	<25> 0 (0%)	<25> 0 (0%)
{Respiratory system}						
nasal cavit	hemangiosarcoma		<25> 0 (0%)	<25> 0 (0%)	<25> 1 (4%)	<25> 0 (0%)
lung	bronchiolar-alveolar adenoma		<25> 2 (8%)	<25> 1 (4%)	<25> 5 (20%)	<25> 4 (16%)
	lymphangioma		1 (4%)	0 (0%)	0 (0%)	0 (0%)
	bronchiolar-alveolar carcinoma		2 (8%)	2 (8%)	2 (8%)	5 (20%)
{Hematopoietic system}						
bone marrow	hemangioma		<25> 1 (4%)	<25> 0 (0%)	<25> 0 (0%)	<25> 0 (0%)
lymph node	malignant lymphoma		<25> 0 (0%)	<25> 0 (0%)	<25> 0 (0%)	<25> 2 (8%)
thymus	malignant lymphoma		<25> 1 (4%)	<25> 0 (0%)	<25> 0 (0%)	<25> 2 (8%)
spleen	hemangiosarcoma		<25> 1 (4%)	<25> 3 (12%)	<25> 1 (4%)	<25> 0 (0%)
{Digestive system}						
stomach	squamous cell papilloma		<25> 0 (0%)	<25> 1 (4%)	<25> 1 (4%)	<25> 1 (4%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 25	67ppm 25	200ppm 25	600ppm 25
{Urinary system}						
urin bladd			<25>	<25>	<25>	<25>
	transitional cell papilloma		1 (4%)	0 (0%)	0 (0%)	0 (0%)
{Reproductive system}						
vagina			<25>	<25>	<25>	<25>
	hemangiosarcoma		0 (0%)	0 (0%)	2 (8%)	0 (0%)
{Special sense organs/appendage}						
Harder gl			<25>	<25>	<25>	<25>
	adenoma		1 (4%)	0 (0%)	0 (0%)	1 (4%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

TABLE M1

NEOPLASTIC LESIONS-INCIDENCE

AND STATISTICAL ANALYSIS : MALE

Group Name	Control	67ppm	200ppm	600ppm
	SITE : subcutis			
	TUMOR : hemangioma, hemangiosarcoma			
Tumor rate				
Overall rates(a)	0/25(0.0)	0/25(0.0)	1/25(4.0)	2/25(8.0)
Adjusted rates(b)	0.00	0.00	4.55	4.17
Terminal rates(c)	0/25(0.0)	0/25(0.0)	0/21(0.0)	1/24(4.2)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1411			
Prevalence method(d)	P = 0.1568			
Combined analysis(d)	P = 0.0466*			
Cochran-Armitage test(e)	P = 0.0589			
Fisher Exact test(e)		P = N.C.	P = 0.5000	P = 0.2449
	SITE : lung			
	TUMOR : bronchiolar-alveolar adenoma			
Tumor rate				
Overall rates(a)	3/25(12.0)	3/25(12.0)	2/25(8.0)	5/25(20.0)
Adjusted rates(b)	12.00	12.00	9.52	20.83
Terminal rates(c)	3/25(12.0)	3/25(12.0)	2/21(9.5)	5/24(20.8)
Statistical analysis				
Peto test				
Standard method(d)	P = ———			
Prevalence method(d)	P = 0.1517			
Combined analysis(d)	P = ———			
Cochran-Armitage test(e)	P = 0.3169			
Fisher Exact test(e)		P = 0.6664	P = 0.5000	P = 0.3510
	SITE : lung			
	TUMOR : bronchiolar-alveolar carcinoma			
Tumor rate				
Overall rates(a)	0/25(0.0)	1/25(4.0)	3/25(12.0)	4/25(16.0)
Adjusted rates(b)	0.00	4.00	14.29	16.67
Terminal rates(c)	0/25(0.0)	1/25(4.0)	3/21(14.3)	4/24(16.7)
Statistical analysis				
Peto test				
Standard method(d)	P = ———			
Prevalence method(d)	P = 0.0226*			
Combined analysis(d)	P = ———			
Cochran-Armitage test(e)	P = 0.0347*			
Fisher Exact test(e)		P = 0.5000	P = 0.1173	P = 0.0549

Group Name	Control	67ppm	200ppm	600ppm
	SITE : lung			
	TUMOR : bronchiolar-alveolar adenoma,bronchiolar-alveolar carcinoma			
Tumor rate				
Overall rates(a)	3/25(12.0)	4/25(16.0)	5/25(.20.0)	8/25(32.0)
Adjusted rates(b)	12.00	16.00	23.81	33.33
Terminal rates(c)	3/25(12.0)	4/25(16.0)	5/21(23.8)	8/24(33.3)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.0312*			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.0626			
Fisher Exact test(e)		P = 0.5000	P = 0.3510	P = 0.0853
	SITE : lymph node			
	TUMOR : malignant lymphoma			
Tumor rate				
Overall rates(a)	0/25(0.0)	0/25(0.0)	2/25(8.0)	0/25(0.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/25(0.0)	0/25(0.0)	0/21(0.0)	0/24(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.4697			
Prevalence method(d)	P = ------			
Combined analysis(d)	P = 0.4697			
Cochran-Armitage test(e)	P = 0.9181			
Fisher Exact test(e)		P = N.C.	P = 0.2449	P = N.C.

Group Name	Control	67ppm	200ppm	600ppm
	SITE : spleen			
	TUMOR : hemangiosarcoma			
Tumor rate				
Overall rates(a)	1/25(4.0)	1/25(4.0)	2/25(8.0)	2/25(8.0)
Adjusted rates(b)	4.00	4.00	4.76	8.33
Terminal rates(c)	1/25(4.0)	1/25(4.0)	1/21(4.8)	2/24(8.3)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3630			
Prevalence method(d)	P = 0.2198			
Combined analysis(d)	P = 0.2441			
Cochran-Armitage test(e)	P = 0.5072			
Fisher Exact test(e)		P = 0.7551	P = 0.5000	P = 0.5000

(HPT360A)

BAIS6

(a): Number of tumor-bearing animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
——— : There is no data which should be statistical analysis.
Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$
N.C. :Statistical value cannot be calculated and was not significant.

STUDY No. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	67ppm	200ppm	600ppm
	SITE : ALL SITE			
	TUMOR : hemangioma, hemangiosarcoma			
Tumor rate				
Overall rates(a)	1/25(4.0)	1/25(4.0)	3/25(12.0)	4/25(16.0)
Adjusted rates(b)	4.00	4.00	9.09	12.50
Terminal rates(c)	1/25(4.0)	1/25(4.0)	1/21(4.8)	3/24(12.5)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1598			
Prevalence method(d)	P = 0.1075			
Combined analysis(d)	P = 0.0558			
Cochran-Armitage test(e)	P = 0.0937			
Fisher Exact test(e)		P = 0.7551	P = 0.3046	P = 0.1743

BAIS5

(a): Number of tumor-beaning animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence retes.
? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
——— : There is no data which should be statistical analysis.
Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$
N.C. :Statistical value cannot be calculated and was not significant.

STUDY No. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	67ppm	200ppm	600ppm
SITE : ALL SITE TUMOR : malignant lymphoma				
Tumor rate				
Overall rates(a)	0/25(0.0)	1/25(4.0)	2/25(8.0)	1/25(4.0)
Adjusted rates(b)	0.00	4.00	0.00	4.17
Terminal rates(c)	0/25(0.0)	1/25(4.0)	0/21(0.0)	1/24(4.2)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.4697			
Prevalence method(d)	P = 0.2409			
Combined analysis(d)	P = 0.3125			
Cochran-Armitage test(e)	P = 0.6609			
Fisher Exact test(e)		P = 0.5000	P = 0.2449	P = 0.5000
SITE : ALL SITE TUMOR : hemangiosarcoma				
Tumor rate				
Overall rates(a)	1/25(4.0)	1/25(4.0)	3/25(12.0)	3/25(12.0)
Adjusted rates(b)	4.00	4.00	9.09	8.33
Terminal rates(c)	1/25(4.0)	1/25(4.0)	1/21(4.8)	2/24(8.3)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1598			
Prevalence method(d)	P = 0.2415			
Combined analysis(d)	P = 0.1289			
Cochran-Armitage test(e)	P = 0.2456			
Fisher Exact test(e)		P = 0.7551	P = 0.3046	P = 0.3046

(HPT360A)

(a) : Number of tumor-bearing animals/number of animals examined at the site.
(b) : Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c) : Observed tumor incidence at terminal kill.
(d) : Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e) : The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
——— : There is no data which should be statistical analysis.
Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$
N.C. :Statistical value cannot be calculated and was not significant.

TABLE M2

NEOPLASTIC LESIONS-INCIDENCE

AND STATISTICAL ANALYSIS : FEMALE

Group Name	Control	67ppm	200ppm	600ppm
	SITE : lung TUMOR : bronchiolar-alveolar adenoma			
Tumor rate				
Overall rates(a)	2/25(8.0)	1/25(4.0)	5/25(20.0)	4/25(16.0)
Adjusted rates(b)	8.70	4.17	20.83	21.05
Terminal rates(c)	2/23(8.7)	1/24(4.2)	5/24(20.8)	4/19(21.1)
Statistical analysis				
Peto test				
Standard method(d)	P = ———			
Prevalence method(d)	P = 0.0708			
Combined analysis(d)	P = ———			
Cochran-Armitage test(e)	P = 0.2521			
Fisher Exact test(e)		P = 0.5000	P = 0.2087	P = 0.3336
	SITE : lung TUMOR : bronchiolar-alveolar carcinoma			
Tumor rate				
Overall rates(a)	2/25(8.0)	2/25(8.0)	2/25(8.0)	5/25(20.0)
Adjusted rates(b)	8.70	8.00	8.33	21.05
Terminal rates(c)	2/23(8.7)	1/24(4.2)	2/24(8.3)	4/19(21.1)
Statistical analysis				
Peto test				
Standard method(d)	P = ———			
Prevalence method(d)	P = 0.0649			
Combined analysis(d)	P = ———			
Cochran-Armitage test(e)	P = 0.1143			
Fisher Exact test(e)		P = 0.6954	P = 0.6954	P = 0.2087
	SITE : lung TUMOR : bronchiolar-alveolar adenoma,bronchiolar-alveolar carcinoma			
Tumor rate				
Overall rates(a)	4/25(16.0)	3/25(12.0)	7/25(28.0)	8/25(32.0)
Adjusted rates(b)	17.39	12.00	29.17	36.84
Terminal rates(c)	4/23(17.4)	2/24(8.3)	7/24(29.2)	7/19(36.8)
Statistical analysis				
Peto test				
Standard method(d)	P = ———			
Prevalence method(d)	P = 0.0415*			
Combined analysis(d)	P = ———			
Cochran-Armitage test(e)	P = 0.0903			
Fisher Exact test(e)		P = 0.5000	P = 0.2481	P = 0.1604

Group Name	Control	67ppm	200ppm	600ppm
	SITE : lymph node TUMOR : malignant lymphoma			
Tumor rate				
Overall rates(a)	0/25(0.0)	0/25(0.0)	0/25(0.0)	2/25(8.0)
Adjusted rates(b)	0.00	0.00	0.00	0.00
Terminal rates(c)	0/23(0.0)	0/24(0.0)	0/24(0.0)	0/19(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0144* ?			
Prevalence method(d)	P = ------			
Combined analysis(d)	P = 0.0144* ?			
Cochran-Armitage test(e)	P = 0.0186*			
Fisher Exact test(e)		P = N.C.	P = N.C.	P = 0.2449
	SITE : thymus TUMOR : malignant lymphoma			
Tumor rate				
Overall rates(a)	1/25(4.0)	0/25(0.0)	0/25(0.0)	2/25(8.0)
Adjusted rates(b)	0.00	0.00	0.00	5.26
Terminal rates(c)	0/23(0.0)	0/24(0.0)	0/24(0.0)	1/19(5.3)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.2857			
Prevalence method(d)	P = 0.1058			
Combined analysis(d)	P = 0.0932			
Cochran-Armitage test(e)	P = 0.1660			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.5000
	SITE : spleen TUMOR : hemangiosarcoma			
Tumor rate				
Overall rates(a)	1/25(4.0)	3/25(12.0)	1/25(4.0)	0/25(0.0)
Adjusted rates(b)	4.35	8.33	4.17	0.00
Terminal rates(c)	1/23(4.3)	2/24(8.3)	1/24(4.2)	0/19(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.5251			
Prevalence method(d)	P = 0.8515			
Combined analysis(d)	P = 0.8974			
Cochran-Armitage test(e)	P = 0.1782			
Fisher Exact test(e)		P = 0.3046	P = 0.7551	P = 0.5000

Group Name	Control	67ppm	200ppm	600ppm
	SITE : vagina			
	TUMOR : hemangiosarcoma			
Tumor rate				
Overall rates(a)	0/25(0.0)	0/25(0.0)	2/25(8.0)	0/25(0.0)
Adjusted rates(b)	0.00	0.00	4.17	0.00
Terminal rates(c)	0/23(0.0)	0/24(0.0)	1/24(4.2)	0/19(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3394			
Prevalence method(d)	P = 0.3386			
Combined analysis(d)	P = 0.4233			
Cochran-Armitage test(e)	P = 0.9181			
Fisher Exact test(e)		P = N.C.	P = 0.2449	P = N.C.

(a): Number of tumor-bearing animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
——— : There is no data which should be statistical analysis.
Significant difference ; * : $P \leqq 0.05$ ** : $P \leqq 0.01$
N.C. :Statistical value cannot be calculated and was not significant.

Group Name	Control	67ppm	200ppm	600ppm
	SITE : ALL SITE TUMOR : malignant lymphoma			
Tumor rate				
Overall rates(a)	1/25(4.0)	0/25(0.0)	0/25(0.0)	4/25(16.0)
Adjusted rates(b)	0.00	0.00	0.00	5.26
Terminal rates(c)	0/23(0.0)	0/24(0.0)	0/24(0.0)	1/19(5.3)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.0296*			
Prevalence method(d)	P = 0.1058			
Combined analysis(d)	P = 0.0073**			
Cochran-Armitage test(e)	P = 0.0094**			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.1743
	SITE : ALL SITE TUMOR : hemangiosarcoma			
Tumor rate				
Overall rates(a)	1/25(4.0)	3/25(12.0)	3/25(12.0)	0/25(0.0)
Adjusted rates(b)	4.35	8.33	8.33	0.00
Terminal rates(c)	1/23(4.3)	2/24(8.3)	2/24(8.3)	0/19(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.5917			
Prevalence method(d)	P = 0.8181			
Combined analysis(d)	P = 0.8465			
Cochran-Armitage test(e)	P = 0.2276			
Fisher Exact test(e)		P = 0.3046	P = 0.3046	P = 0.5000

(a) : Number of tumor-bearing animals/number of animals examined at the site.
(b) : Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c) : Observed tumor incidence at terminal kill.
(d) : Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e) : The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
——— : There is no data which should be statistical analysis.
Significant difference : * : $P \leqq 0.05$ ** : $P \leqq 0.01$
N.C. :Statistical value cannot be calculated and was not significant.

TABLE N1

NUMBER OF ANIMALS WITH TUMORS AND

NUMBER OF TUMORS-TIME RELATED : MALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1
SEX : MALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	67ppm	200ppm	600ppm
1 - 20	NO. OF EXAMINED ANIMALS		0	0	2	0
	NO. OF ANIMALS WITH TUMORS		0	0	2	0
	NO. OF ANIMALS WITH SINGLE TUMORS		0	0	1	0
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	1	0
	NO. OF BENIGN TUMORS		0	0	1	0
	NO. OF MALIGNANT TUMORS		0	0	2	0
	NO. OF TOTAL TUMORS		0	0	3	0
21 - 27	NO. OF EXAMINED ANIMALS		25	25	23	25
	NO. OF ANIMALS WITH TUMORS		4	6	9	16
	NO. OF ANIMALS WITH SINGLE TUMORS		4	5	8	15
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	1	1	1
	NO. OF BENIGN TUMORS		3	4	3	8
	NO. OF MALIGNANT TUMORS		1	3	7	9
	NO. OF TOTAL TUMORS		4	7	10	17
1 - 27	NO. OF EXAMINED ANIMALS		25	25	25	25
	NO. OF ANIMALS WITH TUMORS		4	6	11	16
	NO. OF ANIMALS WITH SINGLE TUMORS		4	5	9	15
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	1	2	1
	NO. OF BENIGN TUMORS		3	4	4	8
	NO. OF MALIGNANT TUMORS		1	3	9	9
	NO. OF TOTAL TUMORS		4	7	13	17

TABLE N2

NUMBER OF ANIMALS WITH TUMORS AND

NUMBER OF TUMORS-TIME RELATED : FEMALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1
SEX : FEMALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	67ppm	200ppm	600ppm
1 - 20	NO. OF EXAMINED ANIMALS		2	0	0	2
	NO. OF ANIMALS WITH TUMORS		2	0	0	2
	NO. OF ANIMALS WITH SINGLE TUMORS		1	0	0	2
	NO. OF ANIMALS WITH MULTIPLE TUMORS		1	0	0	0
	NO. OF BENIGN TUMORS		2	0	0	0
	NO. OF MALIGNANT TUMORS		1	0	0	2
	NO. OF TOTAL TUMORS		3	0	0	2
21 - 27	NO. OF EXAMINED ANIMALS		23	25	25	23
	NO. OF ANIMALS WITH TUMORS		6	7	10	9
	NO. OF ANIMALS WITH SINGLE TUMORS		5	6	8	6
	NO. OF ANIMALS WITH MULTIPLE TUMORS		1	1	2	3
	NO. OF BENIGN TUMORS		4	3	6	6
	NO. OF MALIGNANT TUMORS		3	5	6	7
	NO. OF TOTAL TUMORS		7	8	12	13
1 - 27	NO. OF EXAMINED ANIMALS		25	25	25	25
	NO. OF ANIMALS WITH TUMORS		8	7	10	11
	NO. OF ANIMALS WITH SINGLE TUMORS		6	6	8	8
	NO. OF ANIMALS WITH MULTIPLE TUMORS		2	1	2	3
	NO. OF BENIGN TUMORS		6	3	6	6
	NO. OF MALIGNANT TUMORS		4	5	6	9
	NO. OF TOTAL TUMORS		10	8	12	15

TABLE O1

HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMOR : MALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
REPORT TYPE : A1
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)
ALL ANIMALS (0- 27W)

Organ	Findings	Group Name / No. of Animals on Study	Control	67ppm	200ppm	600ppm
			25	25	25	25
{Respiratory system}						
lung			<25>	<25>	<25>	<25>
	leukemic cell infiltration		0	1	1	0
{Hematopoietic system}						
bone marrow			<25>	<25>	<25>	<25>
	leukemic cell infiltration		0	1	0	0
lymph node			<25>	<25>	<25>	<25>
	leukemic cell infiltration		0	1	0	1
thymus			<24>	<25>	<25>	<25>
	leukemic cell infiltration		0	0	1	0
spleen			<25>	<25>	<25>	<25>
	leukemic cell infiltration		0	0	2	0
{Digestive system}						
liver			<25>	<25>	<25>	<25>
	leukemic cell infiltration		0	0	1	0
{Urinary system}						
kidney			<25>	<25>	<25>	<25>
	leukemic cell infiltration		0	0	1	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

TABLE O2

HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMOR : FEMALE

Organ	Findings	Group Name / No. of Animals on Study	Control	67ppm	200ppm	600ppm
			25	25	25	25
{Respiratory system}						
nasal cavit			<25>	<25>	<25>	<25>
	leukemic cell infiltration		0	0	0	3
lung			<25>	<25>	<25>	<25>
	leukemic cell infiltration		1	0	0	4
{Hematopoietic system}						
bone marrow			<25>	<25>	<25>	<25>
	leukemic cell infiltration		1	0	0	3
lymph node			<25>	<25>	<25>	<25>
	leukemic cell infiltration		1	0	0	2
spleen			<25>	<25>	<25>	<25>
	leukemic cell infiltration		1	0	0	4
{Circulatory system}						
heart			<25>	<25>	<25>	<25>
	leukemic cell infiltration		0	0	0	4
{Digestive system}						
liver			<25>	<25>	<25>	<25>
	leukemic cell infiltration		1	0	0	3
{Urinary system}						
kidney			<25>	<25>	<25>	<25>
	leukemic cell infiltration		0	0	0	3

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control	67ppm	200ppm	600ppm
			25	25	25	25
{Reproductive system}						
ovary			<25>	<25>	<25>	<25>
	leukemic cell infiltration		0	0	0	2
uterus			<25>	<25>	<25>	<25>
	leukemic cell infiltration		1	0	0	3
vagina			<25>	<25>	<25>	<25>
	leukemic cell infiltration		1	0	0	1
{Body cavities}						
mediastinum			<25>	<25>	<25>	<25>
	leukemic cell infiltration		0	0	0	1

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

TABLE P1

HISTOPATHOLOGICAL FINDINGS :

NON-NEOPLASTIC LESIONS : MALE

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 25 1+ (%)	Control 25 2+ (%)	Control 25 3+ (%)	Control 25 4+ (%)	67ppm 25 1+ (%)	67ppm 25 2+ (%)	67ppm 25 3+ (%)	67ppm 25 4+ (%)	200ppm 25 1+ (%)	200ppm 25 2+ (%)	200ppm 25 3+ (%)	200ppm 25 4+ (%)	600ppm 25 1+ (%)	600ppm 25 2+ (%)	600ppm 25 3+ (%)	600ppm 25 4+ (%)
{Respiratory system}																		
nasal cavit			<25>				<25>				<25>				<25>			
	hyperplasia:gland		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
	eosinophilic change:olfactory epithelium		12 (48)	0 (0)	0 (0)	0 (0)	18 (72)	0 (0)	0 (0)	0 (0)	14 (56)	0 (0)	0 (0)	0 (0)	14 (56)	0 (0)	0 (0)	0 (0)
	eosinophilic change:respiratory epithelium		8 (32)	0 (0)	0 (0)	0 (0)	18 (72)	0 (0)	0 (0)	0 * (0)	15 (60)	0 (0)	0 (0)	0 (0)	15 (60)	0 (0)	0 (0)	0 (0)
	respiratory metaplasia:gland		17 (68)	0 (0)	0 (0)	0 (0)	16 (64)	0 (0)	0 (0)	0 (0)	10 (40)	0 (0)	0 (0)	0 (0)	15 (60)	0 (0)	0 (0)	0 (0)
nasopharynx			<25>				<25>				<25>				<25>			
	eosinophilic change		9 (36)	0 (0)	0 (0)	0 (0)	11 (44)	0 (0)	0 (0)	0 (0)	15 (60)	0 (0)	0 (0)	0 (0)	13 (52)	0 (0)	0 (0)	0 (0)
lung			<25>				<25>				<25>				<25>			
	inflammatory infiltration		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
	granulation		0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 25 1+ (%)	Control 25 2+ (%)	Control 25 3+ (%)	Control 25 4+ (%)	67ppm 25 1+ (%)	67ppm 25 2+ (%)	67ppm 25 3+ (%)	67ppm 25 4+ (%)	200ppm 25 1+ (%)	200ppm 25 2+ (%)	200ppm 25 3+ (%)	200ppm 25 4+ (%)	600ppm 25 1+ (%)	600ppm 25 2+ (%)	600ppm 25 3+ (%)	600ppm 25 4+ (%)
{Respiratory system}																		
lung			<25>				<25>				<25>				<25>			
	bronchiolar-alveolar cell hyperplasia		1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
{Hematopoietic system}																		
bone marrow			<25>				<25>				<25>				<25>			
	decreased hematopoiesis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	granulopoiesis:increased		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
thymus			<24>				<25>				<25>				<25>			
	atrophy		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	lymphoid hyperplasia		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)
spleen			<25>				<25>				<25>				<25>			
	deposit of melanin		3 (12)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	5 (20)	0 (0)	0 (0)	0 (0)	2 (8)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 25 1+ (%)	Control 25 2+ (%)	Control 25 3+ (%)	Control 25 4+ (%)	67ppm 25 1+ (%)	67ppm 25 2+ (%)	67ppm 25 3+ (%)	67ppm 25 4+ (%)	200ppm 25 1+ (%)	200ppm 25 2+ (%)	200ppm 25 3+ (%)	200ppm 25 4+ (%)	600ppm 25 1+ (%)	600ppm 25 2+ (%)	600ppm 25 3+ (%)	600ppm 25 4+ (%)
{Hematopoietic system}																		
spleen	extramedullary hematopoiesis	<25>	3 (12)	0 (0)	0 (0)	0 (0)	9 (36)	1 (4)	0 (0)	0 (0)	4 (16)	0 (0)	0 (0)	0 (0)	4 (16)	1 (4)	0 (0)	0 (0)
{Circulatory system}																		
heart	inflammatory infiltration	<25>	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	mesothelial hyperplasia		0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Digestive system}																		
salivary gl	lymphocytic infiltration	<25>	1 (4)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
stomach	erosion:forestomach	<25>	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 25 1+ (%)	Control 25 2+ (%)	Control 25 3+ (%)	Control 25 4+ (%)	67ppm 25 1+ (%)	67ppm 25 2+ (%)	67ppm 25 3+ (%)	67ppm 25 4+ (%)	200ppm 25 1+ (%)	200ppm 25 2+ (%)	200ppm 25 3+ (%)	200ppm 25 4+ (%)	600ppm 25 1+ (%)	600ppm 25 2+ (%)	600ppm 25 3+ (%)	600ppm 25 4+ (%)
[Digestive system]																		
stomach			<25>				<25>				<25>				<25>			
	ulcer:forestomach		2 (8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	squamous cell metaplasia:glandular stomach		0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	squamous cell hyperplasia:forestomach		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
liver			<25>				<25>				<25>				<25>			
	necrosis:central		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
	necrosis:focal		1 (4)	0 (0)	0 (0)	0 (0)	2 (8)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	2 (8)	0 (0)	0 (0)	0 (0)
	inflammatory cell nest		1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	extramedullary hematopoiesis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
	focus of cellular alteration		1 (4)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (8)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 25 1+ (%)	2+ (%)	3+ (%)	4+ (%)	67ppm 25 1+ (%)	2+ (%)	3+ (%)	4+ (%)	200ppm 25 1+ (%)	2+ (%)	3+ (%)	4+ (%)	600ppm 25 1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Urinary system}																		
kidney																		
	tubular necrosis		<25>				<25>				<25>				<25>			
			0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)
	regeneration:renal tubule		0	0	0	0	1	0	0	0	1	0	0	0	2	0	0	0
			(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(8)	(0)	(0)	(0)
{Reproductive system}																		
testis																		
	interstitial cell hyperplasia		<25>				<25>				<25>				<25>			
			0	0	0	0	0	0	0	0	0	0	1	0	0	0	25	0 **
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(100)	(0)
	germ cell necrosis		1	0	0	0	1	0	0	0	8	1	1	0 *	0	0	25	0 **
			(4)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(32)	(4)	(4)	(0)	(0)	(0)	(100)	(0)
epididymis																		
	debris of spermatic elements		<25>				<25>				<25>				<25>			
			1	0	0	0	1	0	0	0	6	0	1	0	0	0	25	0 **
			(4)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(24)	(0)	(4)	(0)	(0)	(0)	(100)	(0)
{Special sense organs/appendage}																		
Harder gl																		
	hyperplasia		<25>				<25>				<25>				<25>			
			0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
			(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 25 1+ (%)	Control 25 2+ (%)	Control 25 3+ (%)	Control 25 4+ (%)	67ppm 25 1+ (%)	67ppm 25 2+ (%)	67ppm 25 3+ (%)	67ppm 25 4+ (%)	200ppm 25 1+ (%)	200ppm 25 2+ (%)	200ppm 25 3+ (%)	200ppm 25 4+ (%)	600ppm 25 1+ (%)	600ppm 25 2+ (%)	600ppm 25 3+ (%)	600ppm 25 4+ (%)
{Body cavities}																		
pleura			<25>				<25>				<25>				<25>			
	mesothelial hyperplasia		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
peritoneum			<25>				<25>				<25>				<25>			
	hemorrhage		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

TABLE P2

HISTOPATHOLOGICAL FINDINGS :

NON-NEOPLASTIC LESIONS : FEMALE

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 25 1+ (%)	Control 25 2+ (%)	Control 25 3+ (%)	Control 25 4+ (%)	67ppm 25 1+ (%)	67ppm 25 2+ (%)	67ppm 25 3+ (%)	67ppm 25 4+ (%)	200ppm 25 1+ (%)	200ppm 25 2+ (%)	200ppm 25 3+ (%)	200ppm 25 4+ (%)	600ppm 25 1+ (%)	600ppm 25 2+ (%)	600ppm 25 3+ (%)	600ppm 25 4+ (%)
[Integumentary system/appandage]																		
skin/app			<25>				<25>				<25>				<25>			
	sebaceous hyperplasia		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
[Respiratory system]																		
nasal cavit			<25>				<25>				<25>				<25>			
	eosinophilic change:olfactory epithelium		10 (40)	0 (0)	0 (0)	0 (0)	14 (56)	0 (0)	0 (0)	0 (0)	9 (36)	0 (0)	0 (0)	0 (0)	12 (48)	0 (0)	0 (0)	0 (0)
	eosinophilic change:respiratory epithelium		15 (60)	0 (0)	0 (0)	0 (0)	17 (68)	0 (0)	0 (0)	0 (0)	8 (32)	2 (8)	0 (0)	0 (0)	10 (40)	1 (4)	0 (0)	0 (0)
	respiratory metaplasia:gland		19 (76)	0 (0)	0 (0)	0 (0)	25 (100)	0 (0)	0 (0)	0 * (0)	21 (84)	0 (0)	0 (0)	0 (0)	24 (96)	0 (0)	0 (0)	0 (0)
	hyperplasia:transitional epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	atrophy:olfactory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
nasopharynx			<25>				<25>				<25>				<25>			
	eosinophilic change		11 (44)	0 (0)	0 (0)	0 (0)	12 (48)	0 (0)	0 (0)	0 (0)	9 (36)	0 (0)	0 (0)	0 (0)	16 (64)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 25 1+ (%)	Control 25 2+ (%)	Control 25 3+ (%)	Control 25 4+ (%)	67ppm 25 1+ (%)	67ppm 25 2+ (%)	67ppm 25 3+ (%)	67ppm 25 4+ (%)	200ppm 25 1+ (%)	200ppm 25 2+ (%)	200ppm 25 3+ (%)	200ppm 25 4+ (%)	600ppm 25 1+ (%)	600ppm 25 2+ (%)	600ppm 25 3+ (%)	600ppm 25 4+ (%)
{Respiratory system}																		
lung			<25>				<25>				<25>				<25>			
	inflammatory infiltration		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	bronchiolar-alveolar cell hyperplasia		1 (4)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Hematopoietic system}																		
bone marrow			<25>				<25>				<25>				<25>			
	congestion		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
	angiectasis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
	decreased hematopoiesis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)
	granulopoiesis:increased		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
thymus			<25>				<25>				<25>				<25>			
	atrophy		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (12)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 25 1+ (%)	Control 25 2+ (%)	Control 25 3+ (%)	Control 25 4+ (%)	67ppm 25 1+ (%)	67ppm 25 2+ (%)	67ppm 25 3+ (%)	67ppm 25 4+ (%)	200ppm 25 1+ (%)	200ppm 25 2+ (%)	200ppm 25 3+ (%)	200ppm 25 4+ (%)	600ppm 25 1+ (%)	600ppm 25 2+ (%)	600ppm 25 3+ (%)	600ppm 25 4+ (%)
[Hematopoietic system]																		
spleen		<25>																
	atrophy		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
	deposit of melanin		2 (8)	0 (0)	0 (0)	0 (0)	3 (12)	0 (0)	0 (0)	0 (0)	2 (8)	0 (0)	0 (0)	0 (0)	4 (16)	0 (0)	0 (0)	0 (0)
	extramedullary hematopoiesis		6 (24)	0 (0)	0 (0)	0 (0)	5 (20)	0 (0)	0 (0)	0 (0)	7 (28)	0 (0)	1 (4)	0 (0)	3 (12)	0 (0)	0 (0)	0 (0)
[Digestive system]																		
salivary gl		<25>																
	lymphocytic infiltration		3 (12)	0 (0)	0 (0)	0 (0)	2 (8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
stomach		<25>																
	ulcer:forestomach		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
	hyperplasia:glandular stomach		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 25 1+ (%)	Control 25 2+ (%)	Control 25 3+ (%)	Control 25 4+ (%)	67ppm 25 1+ (%)	67ppm 25 2+ (%)	67ppm 25 3+ (%)	67ppm 25 4+ (%)	200ppm 25 1+ (%)	200ppm 25 2+ (%)	200ppm 25 3+ (%)	200ppm 25 4+ (%)	600ppm 25 1+ (%)	600ppm 25 2+ (%)	600ppm 25 3+ (%)	600ppm 25 4+ (%)
{Digestive system}																		
stomach		<25>																
	squamous cell hyperplasia:forestomach		0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (8)	1 (4)	0 (0)	0 (0)
small intes		<25>																
	inflammatory infiltration		0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
liver		<25>																
	necrosis:central		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	necrosis:focal		1 (4)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
	degeneration:central		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)
	inflammatory cell nest		1 (4)	0 (0)	0 (0)	0 (0)	2 (8)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
	extramedullary hematopoiesis		0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	2 (8)	0 (0)	0 (0)	0 (0)	2 (8)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 25	67ppm 25	200ppm 25	600ppm 25
{Digestive system}						
liver			<25>	<25>	<25>	<25>
	focus of cellular alteration	1+	1 (4)	0 (0)	1 (4)	1 (4)
		2+	0 (0)	0 (0)	0 (0)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
pancreas			<25>	<25>	<25>	<25>
	islet cell hyperplasia	1+	1 (4)	0 (0)	0 (0)	0 (0)
		2+	0 (0)	0 (0)	0 (0)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
{Urinary system}						
kidney			<25>	<25>	<25>	<25>
	tubular necrosis	1+	0 (0)	0 (0)	0 (0)	1 (4)
		2+	0 (0)	0 (0)	0 (0)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
	regeneration:renal tubule	1+	0 (0)	1 (4)	1 (4)	0 (0)
		2+	0 (0)	0 (0)	0 (0)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
	eosinophilic droplet:proximal tubule	1+	0 (0)	0 (0)	0 (0)	1 (4)
		2+	0 (0)	0 (0)	0 (0)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
urin bladd			<25>	<25>	<25>	<25>
	inflammation	1+	0 (0)	1 (4)	0 (0)	0 (0)
		2+	0 (0)	0 (0)	0 (0)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 25 1+ (%)	2+ (%)	3+ (%)	4+ (%)	67ppm 25 1+ (%)	2+ (%)	3+ (%)	4+ (%)	200ppm 25 1+ (%)	2+ (%)	3+ (%)	4+ (%)	600ppm 25 1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Urinary system}																		
urin bladd			<25>				<25>				<25>				<25>			
	simple hyperplasia:transitional epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Reproductive system}																		
uterus			<25>				<25>				<25>				<25>			
	cystic endometrial hyperplasia		19 (76)	0 (0)	0 (0)	0 (0)	24 (96)	0 (0)	0 (0)	0 (0)	19 (76)	0 (0)	0 (0)	0 (0)	19 (76)	0 (0)	0 (0)	0 (0)
{Special sense organs/appendage}																		
Harder gl			<25>				<25>				<25>				<25>			
	hyperplasia		0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Body cavities}																		
pleura			<25>				<25>				<25>				<25>			
	mesothelial hyperplasia		1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

TABLE Q1

CAUSE OF DEATH : MALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
SEX : MALE

COUSE OF DEATH (SUMMARY)
(0- 27W)

Group Name	Control	67ppm	200ppm	600ppm
Number of Dead and Moribund Animal	0	0	4	1
tumor d:leukemia	0	0	2	0
tumor d:subcutis	0	0	0	1
tumor d:spleen	0	0	1	0
tumor d:oral cavity	0	0	1	0

(BIO120)

TABLE Q2

CAUSE OF DEATH : FEMALE

STUDY NO. : 0886
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl
SEX : FEMALE

COUSE OF DEATH (SUMMARY)
(0- 27W)

Group Name	Control	67ppm	200ppm	600ppm
Number of Dead and Moribund Animal	2	1	1	6
no microscop confirm	0	0	0	2
hematopoietic sy les	0	0	0	1
tumor d:leukemia	1	0	0	3
tumor d:bone marrow	1	0	0	0
tumor d:spleen	0	1	0	0
tumor d:vagina	0	0	1	0

(BIO120)